Oncology Cardiology / Cardiovascular Respiratory / COPD / Asthma Infectious Disease Gastroenterology Diabetes / Metabolic Neurology Women's Health Rheumatology Mental Health / Psychiatry Dermatology Rare Diseases Men's Health
Clinical Trial ● Currently Recruiting Non-phase study NCT02469662

Clinical Outcomes Study of the Nexel Total Elbow

Clinical Outcomes Study of the Nexel Total Elbow — Recruiting • Non-phase study • Infectious Disease • NCT02469662.

📅 09 Jul 2026 ⏱ 1 min read
Currently Recruiting
This trial is actively seeking participants in the UK. Discuss eligibility with your patient before referring.
Status
Currently Recruiting
Phase
Non-phase study
NCT ID
NCT02469662
Start
2015-06
Completion
2035-12
ClinicaliQ Trial Snapshot
  • Clinical Outcomes Study of the Nexel Total Elbow — Recruiting • Non-phase study • Infectious Disease • NCT02469662.
  • Nexel Total Elbow implant study confirms it's safe and works well for new and repeat elbow replacement surgery.

Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.

Use This Page For
  • Quick orientation before opening the registry record.
  • Checking recruitment status, phase and sponsor at a glance.
  • Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying

The objectives of the study are to confirm safety and performance of the Zimmer Nexel Total Elbow when used in primary or revision total elbow replacement. Conditions: Elbow Joint Destruction, Post-traumatic Lesions, Ankylosed Joints, Advanced Rheumatoid Arthritis, Joint Instability or Loss of Motion, Acute Comminuted Articular Fracture of Elbow Joint Surfaces, Bone Loss Contributing to Elbow Instability, Bilateral Ankylosis From Causes Other Than Active Sepsis, Post-traumatic Arthritis, Degenerative Arthritis Interventions: Nexel Total Elbow Lead Sponsor: Zimmer Biomet Planned Enrollment: 134 participants

Full Trial Details
View this trial on the source registry
Eligibility criteria, protocol, and results when available
View Trial ↗
Share: Twitter/X LinkedIn
Related

Related Clinical Intelligence

Guidelines, Drug Science, safety briefs and education connected to this trial area.

Clinical Brief
First person gets new experimental vaccine for Ebola
Infectious Disease · BBC Health · 24 Jul 2026
A new experimental Ebola vaccine has entered human trials, with a UK volunteer as the first recipient, representing progress toward preventing this…
View brief →
Clinical Brief
UKHSA and PACE make new bacteria available to support research into tackling antimicrobial resistance
Infectious Disease · UKHSA · 22 Sep 2026
UKHSA and PACE have made WHO-priority threat bacteria available to researchers, expanding access to organisms critical for antimicrobial resistance (AMR) research and…
View brief →
Clinical Brief
IXCHIQ Chikungunya vaccine: UK marketing authorisation withdrawn following safety review
Infectious Disease · MHRA · 20 Oct 2026
IXCHIQ chikungunya vaccine marketing authorisation withdrawn in UK following CHM safety review, indicating benefit-risk profile no longer favourable Clinicians should cease prescribing…
View brief →
Clinical Brief
£33.2m to protect public from future epidemics and pandemics
Infectious Disease · UKHSA · 08 Oct 2026
Eight new vaccine projects will receive £33.2m funding to develop treatments against high-threat pathogens, enhancing the UK's pandemic preparedness capabilities Funding focuses…
View brief →
Clinical Brief
People Fixing The World
Infectious Disease · BBC Health · 01 Sep 2026
Sepsis Prevention, Detection and Treatment Early recognition is critical – Sepsis remains a major cause of mortality and morbidity; improving awareness and…
View brief →
Clinical Brief
New super flu vaccine rollout begins as NHS regroups from ‘busiest summer’
Infectious Disease · BBC Health · 31 Aug 2026
The NHS is rolling out an updated flu vaccine this season with modifications designed to improve protection against the Super-K strain, reflecting…
View brief →